Two large pharma deals have been announced in the past 24 hours, both involving acquisition of companies with rare disease assets.
The first is Celgene’s $9 bn acquisition of the 90% of Juno Therapeutics it doesn’t already own. Juno is the pioneer of CAR T therapies (oncology immunotherapies) and has multiple R &D stage and marketed cancer therapeutic assets with orphan designation.
In the other M & A deal, Sanofi has stepped up with $11.6 bn to acquire Bioverativ, a company spun off from Biogen last year. Bioverativ specialises in drugs in the rare disease area of haemophilia.
https://www.forbes.com/sites/johann...uno-therapeutics-a-risky-9b-bet/#4d40eb5917c7
https://www.bloomberg.com/news/arti...ear-11-5-billion-deal-for-bioverativ-wsj-says
http://fortune.com/2018/01/22/why-sanofy-is-bying-bioverativ/
2017...2018?, page-175
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.806B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1002 | $14.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 16150 | 7 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |